What Are Wall Street Analysts' Target Price for Gilead Sciences Stock?

Foster City, California-based Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at a market cap of $129.1 billion, the company is renowned for its antiviral therapies, particularly in the treatment of HIV/AIDS, hepatitis B and C, and COVID-19, and is advancing treatments in oncology, inflammatory and respiratory diseases. 

This healthcare giant has considerably outpaced the broader market over the past 52 weeks. Shares of GILD have rallied 58.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 12.3%. Moreover, on a YTD basis, the stock is up 12.2%, compared to SPX’s 3.3% decline.